Page last updated: 2024-12-06
azintamid
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
azintamid: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 71105 |
| CHEMBL ID | 2104678 |
| CHEBI ID | 135068 |
| SCHEMBL ID | 1236142 |
| MeSH ID | M0058166 |
Synonyms (69)
| Synonym |
|---|
| azintamid |
| (6-chlorpyridazin-3-ylthio)diethylacetamide |
| (3-chlor-pyridazinyl-(6)-thio)-essigsaeurediaethylamid [german] |
| brn 0885011 |
| 2-((6-chloro-3-pyridazinyl)thio)-n,n-diethylacetamide |
| einecs 217-384-2 |
| azintamide [inn] |
| n,n-diethyl-2-(6-(3-chloropyridazinyl)mercapto)acetamide |
| (3-chloro-pyridazinyl-(6)-thio)-acetic acid diethylamide |
| ora-gallin |
| azintamida [inn-spanish] |
| nsc 291837 |
| acetamide, 2-((6-chloro-3-pyridazinyl)thio)-n,n-diethyl- |
| x 23 |
| n,n-diethyl-2-(6-(3-chloropyridazinyl)thio)acetamide |
| azintamidum [inn-latin] |
| acetamide, 2-(6-chloro-3-pyridazinylthio)-n,n-diethyl- |
| azintamide (inn) |
| ora-gallin purum |
| colerin (tn) |
| D07485 |
| oragalin |
| 1830-32-6 |
| st 9067 |
| (3-chloro-pyridazinyl-(6)-thio)acetic acid diethylamide |
| wln: t6nnj cg fs1vn2&2 |
| (3-chlor-pyridazinyl-(6)-thio)-essigsaeurediaethylamid |
| oragallin purum |
| colerin |
| biloral |
| oragallin |
| azintamide |
| n,n-diethyl (6-chloropyridazin-3-ylthio)acetamide |
| nsc291837 |
| azinthiamide |
| nsc-291837 |
| oragal |
| bilipurum |
| CHEBI:135068 |
| 2-(6-chloropyridazin-3-yl)sulfanyl-n,n-diethylacetamide |
| acz6l64b41 , |
| azintamidum |
| 5-23-11-00092 (beilstein handbook reference) |
| unii-acz6l64b41 |
| azintamida |
| CHEMBL2104678 |
| st-9067 , |
| azintamide [who-dd] |
| azintamide [mi] |
| azintamide [mart.] |
| SCHEMBL1236142 |
| acetamide,2-[(6-chloro-3-pyridazinyl)thio]-n,n-diethyl- |
| smr004703523 |
| MLS006011938 |
| AC-24006 |
| DTXSID50171370 |
| AKOS025401654 |
| Z221446992 |
| SR-01000945218-1 |
| SR-01000945218-2 |
| sr-01000945218 |
| FT-0733632 |
| DB13992 |
| bilipurum; colerin; oragalin |
| Q27273875 |
| 2-[(6-chloropyridazin-3-yl)sulfanyl]-n,n-diethylacetamide |
| EN300-1700027 |
| CS-0066088 |
| HY-117437 |
Research Excerpts
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| " The changes of symptoms score of upper abdominal distention, upper abdominal pain or discomfort anorexia and effective rate as well as adverse events were recorded." | ( [Efficacy and safety of compound azintamide on dyspepsia symptoms in a multicentre self-controlled trial]. Han, SM; Hao, JY; Liu, YL; Qian, JM; Xie, PY; Xu, L; Yang, YS; Zhang, M; Zhao, HC; Zhu, LM, 2008) | 0.63 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| aryl sulfide | Any organic sulfide in which the sulfur is attached to at least one aromatic group. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 19.92
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (19.92) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (28.57%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (71.43%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||